TransMedics Group, Inc. (NASDAQ:TMDX) Receives $134.50 Consensus PT from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $134.50.

TMDX has been the topic of several recent research reports. Zacks Research downgraded shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Wall Street Zen cut shares of TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research report on Wednesday, July 1st. Stifel Nicolaus upped their target price on TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th.

TransMedics Group Trading Up 1.6%

NASDAQ:TMDX opened at $72.26 on Wednesday. The company has a market capitalization of $2.50 billion, a PE ratio of 16.42 and a beta of 1.89. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. TransMedics Group has a 52-week low of $60.10 and a 52-week high of $156.00. The stock has a fifty day simple moving average of $71.73 and a 200-day simple moving average of $102.84.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the prior year, the firm earned $0.70 earnings per share. TransMedics Group’s quarterly revenue was up 21.2% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group will post 1.88 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. purchased a new stake in shares of TransMedics Group during the fourth quarter worth about $1,788,000. Baillie Gifford & Co. lifted its stake in shares of TransMedics Group by 21.4% during the fourth quarter. Baillie Gifford & Co. now owns 316,473 shares of the company’s stock valued at $38,499,000 after buying an additional 55,754 shares during the period. Candriam S.C.A. lifted its stake in shares of TransMedics Group by 45.4% during the first quarter. Candriam S.C.A. now owns 158,766 shares of the company’s stock valued at $15,783,000 after buying an additional 49,580 shares during the period. M&T Bank Corp boosted its position in TransMedics Group by 749.2% during the fourth quarter. M&T Bank Corp now owns 18,572 shares of the company’s stock worth $2,259,000 after acquiring an additional 16,385 shares during the last quarter. Finally, Zevenbergen Capital Investments LLC boosted its position in TransMedics Group by 8.4% during the fourth quarter. Zevenbergen Capital Investments LLC now owns 280,178 shares of the company’s stock worth $34,084,000 after acquiring an additional 21,655 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.